Oracle: Irrational Post-Earnings Sell-Off As AI Growth Pipeline Remains Intact

Oracle's growth is set for mid-2027, fueled by a $300B OpenAI deal and strong OCI/AI demand. Click here to read my latest ...

Capricor: A Detailed Examination Of Hope-3

Capricor Therapeutics faces high regulatory risks for its DMD therapy. Get expert analysis on trial data and FDA challenges.